Skip to main content
. Author manuscript; available in PMC: 2020 Mar 19.
Published in final edited form as: J Am Coll Cardiol. 2019 Mar 19;73(10):1173–1184. doi: 10.1016/j.jacc.2018.12.053

Figure 4: Down-regulation of ATF3 prevents cAMP-mediated inhibition of the PDE3A INS promoter.

Figure 4:

(A) NRVMs were transfected with siScrambled or siATF3. Cells were harvested 24 or 48 hours after transfection. ATF3 mRNA levels were normalized to 18S. A ~ 5 fold down-regulation of ATF3 was observed. (B) Down-regulation of ATF3 results in increased PDE3A INS polymorphism promoter activity in NRVMs treated with 300 μmol/L N6-Benzoyladenosine-3’,5’-Cyclic monophosphate, sodium salt. These results suggest ATF3 is necessary for regulation of promoter activity in response to higher cAMP levels. ANOVA/ Kruskal-Wallis’ test significance is shown in the Figure (* in comparison to untreated). N.S. – not significant. N= 6–10 different transfections, 3–6 wells/transfection.